Browse

You are looking at 181 - 190 of 4,538 items for

  • Refine by Access: All x
Clear All
Full access

YIA24-004: Liquid Biomarkers of Response to Radium-223 in Metastatic Prostate Cancer

Shuang George Zhao, Grace Blitzer, Jamie Sperger, Menggang Yu, John Floberg, Marina Sharifi, and Joshua Lang

Full access

YIA24-005: MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases

Richard Tobin, Elizabeth N. Katsnelson, Kasey L. Couts, Andrea Spengler, Liyen Loh, Laurent Gapin, and Martin D. McCarter

Full access

YIA24-006: The NF-I/a Transcription Factor is a HIF-Independent Oncogenic Dependency in Kidney Cancer

Jason Scovell, Shannon Zayas, Treg Grubb, Fengshen Kuo, Eduard Reznik, A. Ari Hakimi, and Abhishek Chakraborty

Full access

YIA24-007: Genetic Ancestry and Genomic Alterations of Cervical Cancer in a Diverse Patient Population

Ana Tergas, Sara Byron, Guangfa Zhang, Tyler Izatt, Jiaming Zhang, Nicholas Schork, and Lorna Rodriguez

Full access

Volume 22 (2024): Issue 3 (Apr 2024)

Full access

Aligning With the National Cancer Plan

Erin Frantz, Rachel Darwin, Kimberly Callan, and Wui-Jin Koh

Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024

William G. Wierda, Jennifer Brown, Jeremy S. Abramson, Farrukh Awan, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Matthew Cortese, Larry Cripe, Randall S. Davis, Herbert Eradat, Bita Fakhri, Christopher D. Fletcher, Sameh Gaballa, Muhammad Saad Hamid, Brian Hill, Paul Kaesberg, Brad Kahl, Manali Kamdar, Thomas J. Kipps, Shuo Ma, Claudio Mosse, Shazia Nakhoda, Sameer Parikh, Andrew Schorr, Stephen Schuster, Madhav Seshadri, Tanya Siddiqi, Deborah M. Stephens, Meghan Thompson, Chaitra Ujjani, Riccardo Valdez, Nina Wagner-Johnston, Jennifer A. Woyach, Hema Sundar, and Mary Dwyer

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent’s toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.

Full access

Clinical Risks for Chronic Lymphocytic Leukemia

Jennifer R. Brown

Our understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and includes genetic and environmental factors. CLL is one of the most familial of all cancers, yet common high-penetrance risk alleles have not been identified. Genome-wide association studies have identified many common variants with low relative risks, whereas exome-wide rare variant analysis has implicated ATM in CLL causation. Environmental factors have also been challenging to identify given the limited understanding of the relevant time period of exposure relative to diagnosis, and the inability to quantify past exposures. Agent Orange and glyphosate herbicides have perhaps the most data to support their role. CLL is preceded by a precursor condition called monoclonal B-cell lymphocytosis (MBL), which could therefore be considered a risk factor, but which itself is likely caused by the same risk factors that ultimately give rise to CLL. Although virtually all people with CLL have a preceding MBL phase, most people with MBL will not develop CLL.

Full access

Highlights of the NCCN Oncology Research Program

Full access

NCCN News